Skip to main content

Advertisement

Log in

Immunoglobulins in Adult Sepsis and Septic Shock

  • Sepsis (J Russell, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

For more than 30 years, intravenously administered immunoglobulins (ivIG) have been used to treat primary and secondary syndromes of immune deficiency. Increasing insight into pathomechanisms of severe sepsis and septic shock have led to the implementation of ivIG therapy in the strategies for adjunctive therapy in sepsis in both adults and children. Direct antitoxic effects, as well as indirect immunomodulatory mechanisms of ivIG have been described in the literature and were the basis for the rationale to use these substances in life-threatening infections and hyperinflammatory states. Several clinical trials have been performed, most of them as minor, investigator-initiated protocols. This review summarizes the results of clinical investigations and systematic meta-analyses that have implications for the development of therapeutic strategies, and international guidelines for the management of severe sepsis and septic shock in adult patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gerlach H, Toussaint S. Organ failure in sepsis. Curr Infect Dis Rep. 2007;9:374–81.

    Article  PubMed  Google Scholar 

  2. • Engel C, Brunkhorst FM, Bone H-G, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606–18. Excellent study with a randomized design to exclude biases such as hospital size, seasonal variations etc.

  3. Karlsson S, Varpula M, Roukonen E, et al. Incidence, treatment and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007;33:435–43.

    Article  PubMed  Google Scholar 

  4. EMEA Committee For Proprietary Medicinal Products: note for guidance on plasma-derived medicinal products. CPMP/BPWG/269/95. Ser. 2, London, 1998.

  5. Europäisches Arzneibuch, Monograph No. 918: “Human Immunoglobulins for intravenous application”. Edited by Govi Publisher, Eschborn, Germany, 3rd Edition, 1997.

  6. Gaines A, Varricchio F, Kapit R. Renal insufficiency and failure associated with globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95:2523–9.

    PubMed  CAS  Google Scholar 

  7. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993;91:602–7.

    Article  PubMed  CAS  Google Scholar 

  8. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107–16.

    Article  PubMed  CAS  Google Scholar 

  9. Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis. 1998;26:631–9.

    Article  PubMed  CAS  Google Scholar 

  10. Darenberg J, Söderquist B, Normark BH, Norrby-Teglund A. Differences in Potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis. 2004;38:836–42.

    Article  PubMed  CAS  Google Scholar 

  11. • Schrage B, Duan G, Yang LP, Fraser JD, Proft T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis. 2006;43:743–6. Systematic analysis of the quality of different ivIG preparations demonstrating the potential impact on the design and outcome of clinical trials..

    Article  PubMed  Google Scholar 

  12. Stevens DL. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin Infect Dis. 1998;26:639–41.

    Article  PubMed  CAS  Google Scholar 

  13. Gitlin D, Janeway CA. Agammaglobulinemia: congenital, acquired and transient forms. Prog Hematol. 1956;1:318–29.

    PubMed  CAS  Google Scholar 

  14. Gitlin D, Gross PA, Janeway CA. The gamma globulins and their clinical significance. II. Hypogammaglobulinemia. N Engl J Med. 1959;260:72–6.

    Article  PubMed  CAS  Google Scholar 

  15. Imbach P, Barandun S, Baumgartner C, et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981;36:81–6.

    PubMed  CAS  Google Scholar 

  16. •• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747–55. First class review for readers that are interested in the broad field pathophysiology, pharmacodynamics, of clinical use of ivIG, especially in patients with inflammatory and autoimmune diseases..

    Article  PubMed  CAS  Google Scholar 

  17. Bayry J, Thirion M, Misra N, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003;24:S217–21.

    Article  PubMed  Google Scholar 

  18. •• Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol. 2009;158 Suppl 1:2–13. Our favorite review on the complex pathways by which ivIG preparations exert immunomodulatory effects..

    Article  PubMed  CAS  Google Scholar 

  19. Ramakrishna C, Newo ANS, Shen YW, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathogen. 2011;7:e1002071.

    Article  CAS  Google Scholar 

  20. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol. 2008;45:4073–9.

    Article  PubMed  CAS  Google Scholar 

  21. • Hartung HP, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins (IVIg) – beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158 Suppl 1:23–33. Excellent review especially for readers from the area of neurology and congenital syndromes where ivIG preparations are part of standard therapy..

    Article  PubMed  CAS  Google Scholar 

  22. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1–11.

    Article  PubMed  CAS  Google Scholar 

  23. Moiseeva KG, Nikiforova TV, Kharitonova AI, Koz’minykh LF, Pavlovskaia EN. Intravenous administration of immunoglobulins in young children with staphylococcal infections. Probl Gematol Pereliv Krovi. 1977;2:35–8.

    PubMed  Google Scholar 

  24. Lindquist L, Lundbergh P, Maasing R. Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicaemia and pneumonia. Vox Sang. 1981;40:329–37.

    Article  PubMed  CAS  Google Scholar 

  25. Glinz W, Grob PJ, Nydegger UE, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study. Intensive Care Med. 1985;11:288–94.

    Article  PubMed  CAS  Google Scholar 

  26. Cometta A, Baumgartner JD, Glauser MP. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin Exp Immunol. 1994;97:69–72.

    PubMed  Google Scholar 

  27. Fang KC. Monoclonal antibodies to endotoxin in the management of sepsis. West J Med. 1993;158:393–9.

    PubMed  CAS  Google Scholar 

  28. •• Ziegler EJ, Fisher Jr CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin – a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991;324:429–36. Definitely a “milestone” paper, although the results were disappointing. Readers will learn a lot!.

    Article  PubMed  CAS  Google Scholar 

  29. Albertson TE, Panacek EA, MacArthur RD, et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med. 2003;31:419–27.

    Article  PubMed  Google Scholar 

  30. Christman JW. Potential treatment of sepsis syndrome with cytokine-specific agents. Chest. 1992;102:613–7.

    Article  PubMed  CAS  Google Scholar 

  31. St John RC, Dorinsky PM. Immunologic therapy for ARDS, septic shock, and multiple-organ failure. Chest. 1993;103:932–43.

    Article  PubMed  CAS  Google Scholar 

  32. Reinhart K, Menges T, Gardlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med. 2001;29:765–9.

    Article  PubMed  CAS  Google Scholar 

  33. Opal SM, Fisher Jr CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25:1115–24.

    Article  PubMed  CAS  Google Scholar 

  34. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis. 2009;49:1369–76.

    Article  PubMed  Google Scholar 

  35. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome – a comparative observational study. Clin Infect Dis. 1999;28:800–7.

    Article  PubMed  CAS  Google Scholar 

  36. • Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333–40. The most important study on ivIG in streptococcal toxic shock syndrome, still being the base for recommendations for the use of ivIG in these patients..

    Article  PubMed  CAS  Google Scholar 

  37. Valiquette L, Low DE, McGeer AJ. Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult question. Clin Infect Dis. 2009;49:1377–9.

    Article  PubMed  Google Scholar 

  38. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002;34:1084–93.

    Article  PubMed  CAS  Google Scholar 

  39. Bloos F, Reinhart K. New treatment approaches in sepsis. Zentralbl Chir. 2002;127:174–9.

    Article  PubMed  CAS  Google Scholar 

  40. Laupland KB. Polyclonal intravenous immunoglobulin for the treatment of infection in critically ill patients. Can J Infect Dis. 2002;13:100–6.

    Google Scholar 

  41. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;1:CD001090. http://www.ncbi.nlm.nih.gov/pubmed/11869591. Accessed 6 August 2012.

  42. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39:38–46.

    Article  PubMed  CAS  Google Scholar 

  43. Norrby-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006;260:509–16.

    Article  PubMed  CAS  Google Scholar 

  44. Turgeon AF, Hutton B, Fergusson DA, et al. Metaanalysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146:193–203.

    PubMed  Google Scholar 

  45. • Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35:2686–92. Although all of the meta-analyses from Ref. 41 to Ref. 48 are important, this one was performed in a sound matter..

    Article  PubMed  CAS  Google Scholar 

  46. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677–85.

    Article  PubMed  CAS  Google Scholar 

  47. • Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock (review). Cochrane Library. 2010; doi:10.1002/14651858.CD001090. Together with Ref. 41, this review is the confirming analysis for the limited evidence on the use of ivIG in adult patients with sepsis.

  48. •• Soares MO, Welton NJ, Harrison DA, et al. An evaluation of the feasibility, cost and value of information of a multicenter randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012;16:1–186. Definitely a “must” for everybody who wants sufficient information on this topic. Many sub-analyses, many graphs, something like a “handbook” for EBM in severe sepsis..

    PubMed  CAS  Google Scholar 

  49. •• Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med. 2007;35:2693–701. The most important RCT on ivIG in adult patients with severe sepsis..

    Article  PubMed  CAS  Google Scholar 

  50. • Brocklehurst P, Farrell B, King A, for the INIS Collaborative Group, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365:1201–11. Extremely important, large RCT, although limited to very low weight newborns..

    Article  PubMed  Google Scholar 

  51. Burns ER, Lee V, Rubinstein A. Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol. 1991;11:363–8.

    Article  PubMed  CAS  Google Scholar 

  52. • Hentrich M, Fehnle K, Ostermann H, et al. IgM-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med. 2006;34:1319–25. The only available, good quality trial on the use of IgM-enriched ivIG in adult septic patients..

    Article  PubMed  CAS  Google Scholar 

  53. Rodriguez A, Rello J, Neira J, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005;23:298–304.

    Article  PubMed  CAS  Google Scholar 

  54. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281–6.

    Article  PubMed  CAS  Google Scholar 

  55. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev. 1997;9(Suppl):15–21.

    PubMed  CAS  Google Scholar 

  56. Trzeciak S, Zanotti-Cavazzoni S, Parrillo JE, Dellinger RP. Inclusion criteria for clinical trials in sepsis: did the American College of Chest Physicians/Society of Critical Care Medicine consensus conference definitions of sepsis have an impact? Chest. 2005;127:242–5.

    Article  PubMed  Google Scholar 

  57. Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med. 1991;19:1104–13.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Herwig Gerlach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toussaint, S., Gerlach, H. Immunoglobulins in Adult Sepsis and Septic Shock. Curr Infect Dis Rep 14, 522–529 (2012). https://doi.org/10.1007/s11908-012-0287-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-012-0287-z

Keywords

Navigation